Vericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:
|What:||Vericel Corporation Second-Quarter 2016 Earnings Call|
|When:||Monday, August 8, 2016 at 4:30pm (ET)|
|How:||The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.|
|To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation second-quarter 2016 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.|
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until August 8, 2017. A replay of the call will also be available until 11:59 pm (EDT) on August 12, 2016 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 57713501.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
CONTACT: Chad Rubin The Trout Group firstname.lastname@example.org (646) 378-2947 or Lee Stern The Trout Group email@example.com (646) 378-2922